September 15th 2025
FLAURA2 data show osimertinib plus chemotherapy significantly improves overall survival vs osimertinib alone in frontline EGFR+ advanced NSCLC.
September 12th 2025
Sintilimab Plus Chemotherapy Induces Superior Survival in EGFR-Mutated Nonsquamous NSCLC
October 19th 2021Sintilimab, a bevacizumab biosimilar injection, met the primary end point of the phase 3 ORIENT-31 trial by significantly increasing progression-free survival in patients with EGFR-mutated, nonsquamous, non–small cell lung cancer.
Neoadjuvant Triplet Regimen Safe, Effective in Patients With Resectable Mesothelioma
September 14th 2021Updates from the ongoing S1619 trial suggest that a triplet combination regimen of neoadjuvant cisplatin, pemetrexed, and atezolizumab is effective and tolerable in the treatment of patients with resectable pleural mesothelioma.
CheckMate-73L To Explore Ipilimumab and Nivolumab Combo in Non-Small Cell Lung Cancer Treatment
August 18th 2021The ongoing CheckMate-73L trial seeks to determine if nivolumab plus ipilimumab following nivolumab plus chemoradiation could become the new standard of care in treating non-small cell lung cancer, says Nagla F. Abdel Karim, MD.
Race, Socioeconomic Factors May Impact Survival Outcome in Limited-Stage Small Cell Lung Cancer
July 31st 2021African American, Asian, and Hispanic patients with limited-stage small cell lung cancer displayed superior survival outcomes compared with White patients, indicating that race might be linked with survival in this disease.